Skip to search formSkip to main contentSkip to account menu

anacetrapib

A cholesteryl ester transfer protein (CETP) inhibitor with hypocholesterolemic properties. Anacetrapib reduces the transfer of cholesteryl ester from… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Anticholesteremic AgentsOxazolidinones
MK 0859

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Impact of ADCY9 Genotype on Response to Anacetrapib
Supplemental Digital Content is available in the text. 
Review
2018
Review
2018
CETP inhibition, statins and diabetes.
Review
2018
Review
2018
Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk.
2017
2017
CETP Inhibitors - A New Inning?
Former baseball manager Tony La Russa once said, “Even when you have three strikes, you’re still not out. There is always… 
Highly Cited
2012
Highly Cited
2012
Tangier disease: epidemiology, pathophysiology, and management.
Tangier disease is one of the most severe forms of familial high-density lipoprotein (HDL) deficiency. Since its discovery it has… 
2011
2011
Learning lessons from Pfizer's $800 million failure
2011
2011
Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects
A (MK-0859) is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP) currently undergoing development as… 
Review
2011
Review
2011
Emerging therapeutic strategies to enhance HDL function
Epidemiologic studies indicate a strong inverse correlation between plasma levels of high-density lipoproteins (HDL) and… 
Review
2009
Review
2009
The end of the road for CETP inhibitors after torcetrapib?
Purpose of review Because high-density lipoprotein cholesterol (HDL-C) levels are inversely related to cardiovascular disease… 
Review
2009
Review
2009
Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Anacetrapib, under development by Merck & Co Inc, is an inhibitor of the cholesterol ester transfer protein (CETP) for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)